A new variant of COVID-19 identified in Botswana and Nigeria with dozens of mutations is being watched closely, amid fears it could be resistant to the effect of currently-used vaccines. The B.1.1.529 variant has more mutations affecting the spike protein targeted by vaccines than any other strain identified to date, although it’s not yet clear
In response to the COVID-19 pandemic, vaccines for SARS-CoV-2 were developed, tested, and introduced at a remarkable speed. Although the vaccine introduction had a major impact on the evolution of COVID-19, some potential rare side-effects of the vaccines were observed. Within a short period, three scientific groups from Norway, Germany, and the UK reported cerebral
Research into the way our immune systems respond to COVID-19 reveals the sex of a patient may affect how well drugs work Anew study from the University of Calgary shows how dexamethasone, the main treatment for severe COVID-19 lung infections, alters how immune cells work, which may help male patients, but has little to no benefit for
Vaccines are less effective against some COVID-19 variants and boosting may be required within one year to maintain efficacy above 50 per cent, according to a new study. The researchers from the Sydney Institute for Infectious Diseases at the University of Sydney, UNSW Sydney’s Kirby Institute and the University of Melbourne’s Doherty Institute have conducted an analysis
The object of the study was to verify if early administration of convalescent plasma obtained from blood donors who have recovered from coronavirus disease 2019 (Covid-19) could prevent disease progression in acutely ill, high-risk patients with Covid-19. In this randomized, multicenter, single-blind trial, we assigned patients who were being treated in an emergency department for
Over the course of this pandemic, significant progress has been made in treating COVID-19 and helping to save lives. That progress includes the development of life-preserving monoclonal antibody infusions and repurposing existing drugs, to which NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership has made a major contribution. But for many months we’ve had hopes that a
Clotting problems and resulting complications are common in COVID-19 patients. Researchers at the Medical University of Vienna have now shown that a member of the anticoagulant group of drugs not only has a beneficial effect on survival of COVID-19 patients, but also influences the duration of active infection with the SARS-CoV-2 coronavirus. The results were
As we’ve seen during the COVID-19 pandemic, serious infections sometimes trigger an excessive inflammatory reaction that does as much harm — or more — than the infection itself. New research at Boston Children’s Hospital and Brigham and Women’s Hospital suggests a potential way to block this hyperinflammation response by repurposing or modifying an existing drug.
Different SARS-CoV-2 vaccines are approved in various countries, but few direct comparisons of the antibody responses they stimulate have been reported. In thi paper the authors collected plasma specimens in July 2021 from 196 Mongolian participants fully vaccinated with one of four COVID-19 vaccines: Pfizer/BioNTech, AstraZeneca, Sputnik V and Sinopharm. Functional antibody testing with a
As millions of eligible people consider getting a booster shot, many are wondering what the data tells us about the effectiveness of the vaccines, and how much their protection might be waning. The good news is that a growing body of research shows that the vaccines authorized remain highly protective against severe disease and hospitalization
